

**Baystate Infectious Diseases Clinical Research
CURRENT STUDIES**

SOON TO OPEN	STUDY TITLE	PHASE	PI
START	<p style="text-align: center;">Strategic Timing of AntiRetroviral Treatment</p> <p style="text-align: center;">Funded by: Division of AIDS, The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)</p>	II	Skiest

OPEN TO ENROLLMENT	STUDY TITLE	PHASE	PI
<p>FLU 003 <i>Nationwide =1000</i> <i>BMC = 50</i></p>	<p style="text-align: center;">An International Observational Study to Characterize Adults Who Are Hospitalized with Complications of Influenza A -- Pandemic H1N1 FLU 003. A Multicenter Study of the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)</p>		Paez
<p>POEM <i>Nationwide =3000</i> <i>BMC = Unlimited</i></p>	<p style="text-align: center;">An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment Experienced Hiv 1 Infected Patients</p>	IV	Skiest

CLOSED TO ENROLLMENT	STUDY TITLE	PHASE	PI
<p>Wyeth 13vPnc 6115A1-3017 <i>N =330 BMC = 30</i></p>	<p style="text-align: center;">Open-Label, Single-Arm Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 3 Doses Of 13- Valent Pneumococcal Conjugate Vaccine In Human Immunodeficiency Virus-Injected Subjects 18 Years Of Age Or Older Who Have Been Previously Immunized With 23-Valent Pneumococcal Polysaccharide Vaccine.</p>	III	Skiest
<p>Swift GS US 164-0216 <i>N =340 BMC = 5</i></p>	<p style="text-align: center;">The SWIFT Study: A Prospective, Randomized, Open-Label Phase IV Study to Evaluate the Rationale of Switching from Fixed-Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed-Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically-Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Regimen</p>	IV	Skiest

**Baystate Infectious Diseases Clinical Research
CURRENT STUDIES**

Page 2

CLOSED TO ENROLLMENT	STUDY TITLE	PHASE	PI
GS-US-236-0103 <i>N = 700 BMC = 5</i>	Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS 9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults	III	Paez
GS-US-236-0102 <i>N = 700 BMC = 5</i>	Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults	III	Paez
Prophesys 3 MV21542 <i>N = 1400 BMC = 5</i>	A Prospective observational study on predictors of early on-treatment response and sustained virological response in a cohort of treatment naïve HCV-infected patients treated with pegylated interferone	IV	Paez
Pfizer A4001078 <i>N = 88 BMC = 5</i>	Pilot Study of Novel Combination of Maraviroc + Atazanavir/Ritonavir Vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Treatment Naïve HIV-Infected Patients With R5 HIV-1	II	Paez
GS US 183 0130 Intergrase Inhibitor	Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS 9137 (GS 9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV 1 Infected Subjects	II	Skiest